Juan-Rivera Maylein C, Martínez-Ferrer Magaly
Department of Pharmaceutical Sciences, School of Pharmacy, University of Puerto Rico, Medical Sciences Campus, San Juan, PR 00936, USA.
University of Puerto Rico Comprehensive Cancer Center, Medical Sciences Campus, San Juan, PR 00936, USA.
Cancers (Basel). 2018 Feb 6;10(2):44. doi: 10.3390/cancers10020044.
Prostate cancer (PCa) is the most frequently diagnosed cancer and the third highest cause of cancer-related deaths in men in the U.S. The development of chemotherapeutic agents that can bind PCa tumor cells with high specificity is critical in order to increase treatment effectiveness. Integrin receptors and their corresponding ligands have different expression patterns in PCa cells. They have been identified as promising targets to inhibit pathways involved in PCa progression. Currently, several compounds have proven to target specific integrins and their subunits in PCa cells. In this article, we review the role of integrins inhibitors in PCa and their potential as therapeutic targets for PCa treatments. We have discussed the following: natural compounds, monoclonal antibodies, statins, campothecins analog, aptamers, d-aminoacid, and snake venom. Recent studies have shown that their mechanisms of action result in decrease cell migration, cell invasion, cell proliferation, and metastasis of PCa cells.
前列腺癌（PCa）是美国男性中最常被诊断出的癌症，也是癌症相关死亡的第三大原因。开发能够高度特异性结合前列腺癌细胞的化疗药物对于提高治疗效果至关重要。整合素受体及其相应配体在前列腺癌细胞中具有不同的表达模式。它们已被确定为抑制前列腺癌进展相关途径的有希望的靶点。目前，几种化合物已被证明可靶向前列腺癌细胞中的特定整合素及其亚基。在本文中，我们综述了整合素抑制剂在前列腺癌中的作用及其作为前列腺癌治疗靶点的潜力。我们讨论了以下内容：天然化合物、单克隆抗体、他汀类药物、喜树碱类似物、适体、d-氨基酸和蛇毒。最近的研究表明，它们的作用机制导致前列腺癌细胞的细胞迁移、细胞侵袭、细胞增殖和转移减少。
